Press release
Investigation announced for Long-Term Investors in shares of Altimmune, Inc. (NASDAQ: ALT) over potential Wrongdoing
An investigation was announced for long-term investors in shares of Altimmune, Inc. (NASDAQ: ALT) concerning potential breaches of fiduciary duties by certain directors and officers of Altimmune, Inc.Investors who are current long term investors in Altimmune, Inc. (NASDAQ: ALT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ALT stocks follows a lawsuit filed against Altimmune, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ALT stocks, concerns whether certain Altimmune, Inc. (directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug's efficacy and tolerability results observed in the MOMENTUM Trial, that accordingly, the MOMENTUM Trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than Defendants had led investors to believe, that as a result of all the foregoing, Defendants had overstated Altimmune's prospects for finding a strategic partner to develop pemvidutide, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Altimmune, Inc. (NASDAQ: ALT) over potential Wrongdoing here
News-ID: 3867995 • Views: …
More Releases from Shareholders Foundation, Inc.

Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…

Lawsuit Alert: Investors who lost money with shares of RCI Hospitality Holdings, …
An investor, who purchased shares of RCI Hospitality Holdings, Inc. (NASDAQ: RICK), filed a lawsuit over alleged violations of Federal Securities Laws by RCI Hospitality Holdings, Inc.
Investors who purchased shares of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) have certain options and for certain investors are short and strict deadlines running. Deadline: November 20, 2025. NASDAQ: RICK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…

Lawsuit filed for Investors who lost money with shares of Quanex Building Produc …
An investor, who purchased shares of Quanex Building Products Corporation (NYSE: NX), filed a lawsuit over alleged violations of Federal Securities Laws by Quanex Building Products Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Quanex Building Products Corporation (NYSE: NX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NYSE: NX investors should contact the Shareholders…

PubMatic, Inc. (NASDAQ: PUBM) Investor Alert: Deadline in Lawsuit on October 20, …
A deadline is coming up on October 20, 2025 in the lawsuit filed for certain investors of PubMatic, Inc. (NASDAQ: PUBM) over alleged securities laws violations by PubMatic, Inc.
Investors who purchased shares of PubMatic, Inc. (NASDAQ: PUBM) have certain options and there are strict and short deadlines running. Deadline: October 20, 2025. PubMatic, Inc. (NASDAQ: PUBM) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Altimmune
Altimmune, Inc. (NASDAQ: ALT) Investor Alert: Deadline in Lawsuit on October 6, …
A deadline is coming up on October 6, 2025 in the lawsuit filed for certain investors of Altimmune, Inc. (NASDAQ: ALT) over alleged securities laws violations by Altimmune, Inc.
Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and there are strict and short deadlines running. Deadline: October 6, 2025. NASDAQ: ALT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Lawsuit filed for Investors who lost money with shares of Altimmune, Inc. (NASDA …
An investor, who purchased shares of Altimmune, Inc. (NASDAQ: ALT), filed a lawsuit over alleged violations of Federal Securities Laws by Altimmune, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and for certain investors are short and strict deadlines running. Deadline: October 6, 2025. NASDAQ: ALT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Nasal Vaccines Market Top Companies Study - Vaxart, Inc, FluGen Inc, Altimmune, …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Nasal Vaccines Market - Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, and Conjugate Vaccines), By Application (Influenza, COVID-19), Trends, Industry Competition Analysis, Revenue And Forecast To 2034."
The Global Nasal Vaccines Market is estimated to reach over USD 935.2 Mn by 2034, exhibiting a CAGR of 8.6% during the forecast period.
Get Free Access…
Biodefense Market Future Business Opportunities 2025-2032 | XOMA corporation, Al …
Latest Report, titled "Biodefense Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Biodefense market has been expanding significantly in recent…
Deadline on July 5th coming up in Lawsuit for Investors in Altimmune, Inc. (NASD …
A deadline is coming up on July 5, 2024 in the lawsuit filed for certain investors of Altimmune, Inc. (NASDAQ: ALT) over alleged securities laws violations by Altimmune, Inc.
Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and there are strict and short deadlines running. Deadline: July 5, 2024. NASDAQ: ALT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to…
Lawsuit filed for Investors who lost money with shares of Altimmune, Inc. (NASDA …
An investor, who purchased shares of Altimmune, Inc. (NASDAQ: ALT), filed a lawsuit over alleged violations of Federal Securities Laws by Altimmune, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and for certain investors are short and strict deadlines running. Deadline: July 5, 2024. NASDAQ: ALT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…